ArticleObstetrics & gynecology science2026
Role of serum Netrin-1 and urinary kidney injury molecule-1 in risk stratification of preeclampsia.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePreeclampsia (PE) is a leading cause of maternal and perinatal morbidity and mortality worldwide. Identifying reliable biomarkers may improve risk prediction and disease stratification. To evaluate serum Netrin-1 and urinary kidney injury molecule-1 (KIM-1) levels in preeclamptic women compared with those in healthy pregnant women and to assess their association with disease severity and maternal-fetal outcomes.
methodsA prospective observational study was conducted at a tertiary care referral center in Western Rajasthan between September 2023 and March 2025, enrolling 118 pregnant women (59 PE cases and 59 controls). Serum Netrin-1 and urinary KIM-1 levels were correlated with PE severity, maternal complications, and fetal outcomes.
resultsPreeclamptic women had significantly higher serum Netrin-1 (844.55±195.27 pg/mL) and urinary KIM-1 (1.57±0.75 ng/mg creatinine) levels than controls (378.24±127.75 pg/mL and 0.62±0.29 ng/mg; P<0.0001). Biomarker levels were higher in patients with severe PE and maternal complications. Receiver operating characteristic curve analysis demonstrated excellent diagnostic accuracy for serum Netrin-1 (area under the curve [AUC], 0.993) and very good accuracy for urinary KIM-1 (AUC, 0.916).
conclusionSerum Netrin-1 and urinary KIM-1 levels are promising biomarkers for PE diagnosis and risk stratification. Serum Netrin-1 levels show excellent discriminatory potential and may support clinical risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.